Kurve Therapeutics
Bypassing the Blood-Brain Barrier
Kurve is investigating its revolutionary technology in several CNS (Central Nervous System) disorders. More than 15 human use clinical trials with our technology have been conducted so far. We hope to change the landscape of cognitive aging, neurodegenerative disease, and related disorders. Alzheimer’s, Parkinson’s, PTSD, and Multiple Sclerosis are a few of the many CNS disorder treatments we are investigating.
Our drug delivery technology is designed to target the most difficult part of the treatment process — getting medication through the blood-brain barrier.
About Us
Our key invention is our patented Controlled Particle Dispersion® (CPD) intranasal drug delivery technology. This next-generation technology creates a focused, turbulent flow that navigates the curved pathways of the nasal cavity, allowing access to the olfactory region.
Our goal is to advance next-generation treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the BBB at the top of the nasal cavity.
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, our mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body dementia, Parkinson’s disease, and ALS. The Kurve technology is featured in 18 peer-reviewed publications in leading medical journals. Kurve technology has been used in five double-blind placebo-controlled Phase II studies and is ready for Phase III with Alzheimer’s patients.
Marc Giroux is the founder and CEO of Kurve Therapeutics.
His passion and expertise have made him the inventor of record for 26 existing and pending patents that underpin Kurve’s intellectual property.
A winner of multiple industry awards, Marc has dedicated his career to the high-tech manufacturing sector where he conceives and develops new and innovative products.
MARC GIROUX,
Chairman and Chief Executive Officer
Dr. Glenn Cornett has been developing drugs for psychiatric and neurological indications for over a decade, including a drug currently entering Phase II clinical trials for autism.
He has a neuroscience Ph.D. from UCLA and an M.D. with a Distinction in Research from the University of Michigan.
After founding Navitas Pharma and building a career working for companies such as McKinsey, Eli Lilly, Razorfish, and Los Alamos National Laboratory, Dr. Cornett cemented himself as an industry expert dedicated to improving and saving lives.
GLENN CORNETT, M.D., PH.D.,
Chief Science Officer
Marc Giroux is the founder and CEO of Kurve Therapeutics.
His passion and expertise have made him the inventor of record for 26 existing and pending patents that underpin Kurve’s intellectual property.
A winner of multiple industry awards, Marc has dedicated his career to the high-tech manufacturing sector where he conceives and develops new and innovative products.
MARC GIROUX,
Chairman and Chief Executive Officer
Dr. Glenn Cornett has been developing drugs for psychiatric and neurological indications for over a decade, including a drug currently entering Phase II clinical trials for autism.
He has a neuroscience Ph.D. from UCLA and an M.D. with a Distinction in Research from the University of Michigan.
After founding Navitas Pharma and building a career working for companies such as McKinsey, Eli Lilly, Razorfish, and Los Alamos National Laboratory, Dr. Cornett cemented himself as an industry expert dedicated to improving and saving lives.
GLENN CORNETT, M.D., PH.D.,
Chief Science Officer
With over forty years of experience and success, Tom is an accomplished CFO with a background in accounting, financial reporting, investment banking, mergers and acquisitions.
Highly regarded in the private equity industry, Tom has a successful track record of stabilizing and growing a variety of businesses. Among his many skills, he thrives in creating function in dysfunctional accounting structures.
Tom S. McDowell,
Chief Operating Officer
Patients
Living with a CNS disorder does not have to be an isolating or frustrating experience. Visit the patient page to learn more about current clinical trials, answers to frequently asked questions, and additional educational resources.
Physicians
Review the clinical trials in which Kurve Therapeutics has been studied, case studies and peer-reviewed published work to gain a 360-degree view of Kurve Therapeutics’ technology.
Pharmaceutical Manufacturers
Visit the Pharmaceutical page for information on Kurve Therapeutics’ groundbreaking medical technology. Learn more about clinical trials, our investigational Controlled Particle Dispersion® device (CPD), and how our technology could fit into your drug development program.
Investors
Get information on investment opportunities, press releases, market trends, and the path to launch. Learn how you can invest in breakthrough medtech innovations and be a part of our efforts to change the CNS disorder treatment landscape.
Recent News
Get information on investment opportunities, press releases, market trends, and the path to launch. Learn how you can invest in breakthrough medtech innovations and be a part of our efforts to change the CNS disorder treatment landscape.
